Image 1_Exploration of the diagnostic and prognostic roles of decreased autoantibodies in lung cancer.tif حسب Ying Ye (72583)

"…A follow-up process for 13 patients diagnosed with early-stage lung cancer revealed that 10 of the 15 decreased autoantibodies would recover to a higher level after the tumor was resected. …"

Long-term anti-nucleocapsid response by baseline patient characteristics. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Association of each health behavior and the reported decrease in psychological well-being during the pandemic between individuals who often/very often compared to rarely/never engaged in health behaviors.... حسب Elie Mulhem (22537863)

"…<p>Association of each health behavior and the reported decrease in psychological well-being during the pandemic between individuals who often/very often compared to rarely/never engaged in health behaviors. …"

Effect of each health behavior on the reported decrease in physical health during the pandemic between individuals who often/very often compared to rarely/never engaged in health behaviors.... حسب Elie Mulhem (22537863)

"…<p>Effect of each health behavior on the reported decrease in physical health during the pandemic between individuals who often/very often compared to rarely/never engaged in health behaviors. …"

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to Ensovibep vs placebo day 1–90. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

K1 expression decreases in HA15 treated cells. حسب Guillermo Najarro (19964572)

Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Plots of FEV₁ (upper left), FVC (upper right), TLC (lower left) and TLCO (lower right) values expressed in % pred. (<i>y</i>-axis) against <i>z</i>-scores (<i>x</i>-axis... حسب Piotr W. Boros (21446186)

الموضوعات:

Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Cancer virtual patients with decreased initial neutrophil concentrations have higher viral load peaks. حسب Sonia T. Gazeau (21512764)

"…<p><b>A)</b> Viral loads in mild <b>a</b><b>-c)</b> and severe virtual patients <b>d</b><b>-f)</b>. <b>B)</b> Sensitivity analysis determined that decreasing <i>N</i>0 (the initial concentration of neutrophils) causes higher peak viral load and peak IL-6 and IFN concentrations.…"

Loss of <i>Rab23</i> decreases ciliation in MEFs and Tbr1 + intermediate progenitors. حسب Wan Ying Leong (22075947)

<i>RTTN</i>-mutated organoids exhibit decreased proliferation and increased cell death at early stages. حسب Justine Guguin (9088672)

ECoG timescales decrease during spatial attention. حسب Isabel Raposo (21615517)

"…If power was above the threshold (<i>z</i> > 1.96) for a minimum of 10% of the time window (500 ms) after the cue, the channel was considered hemifield-selective. …"